Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FESOTERODINE FUMARATE

All products: Limited Use (codes 290)

Other products in the same Health Canada class (G04BD) — coverage varies; not interchangeable

  • Mirabegron (Myrbetriq): limited Use 290
  • Propiverine (Mictoryl Pediatric): limited Use 530

Toviaz · DIN 02380021 · 4mg · tablet

Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Toviaz · DIN 02380021 Manufacturer: Pfizer Canada Inc.; listing date 2013-04-30 Health Canada: Marketed since 2012-04-19 · brand TOVIAZ · ATC G04BD11 FESOTERODINE · form Tablet (extended-release) · route Oral · ingredients FESOTERODINE FUMARATE 4 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.7500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86587 · Verify on the e-Formulary ↗ (DIN 02380021)

Source record
DIN 02380021: Toviaz Raw flags: sec12=Y, sec3=Y Item: 860000072; group id 875; item number 2113; lccId 00233; manufacturer id PFI Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.5794; ministry $0.7500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380021 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86587
Interchangeable products
Ach-Fesoterodine · DIN 02535998 · $0.7500 Sandoz Fesoterodine Fumarate · DIN 02521768 · $0.7500
Shortage status: resolved shortage (ended 2022-06-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380021
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (86:00 SPASMOLYTICS) and how they are covered

Matched class: 86:00 SPASMOLYTICS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: OXTRIPHYLLINE Some products covered without a code (check the product listing): THEOPHYLLINE ANHYDROUS 86:00 SPASMOLYTICS

MIRABEGRON

· 5 products · Limited Use, codes 290 · strengths: 25mg, 50mg · ER Tab

OXTRIPHYLLINE

· 1 products · General benefit · strengths: 20mg/mL · O/L

THEOPHYLLINE ANHYDROUS

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 400mg, 600mg · SR Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:00 86:12:04 Antimuscarinics

PROPIVERINE HYDROCHLORIDE

· 1 products · Limited Use, codes 530 · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:12:04
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Toviaz (fesoterodine fumarate) is indicated for: • The treatment of patients with overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence or any combination of these symptoms. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Toviaz in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics; 8 ADVERSE REACTIONS, 8.2 Clinical Trial Adverse Drug Reactions, 8.2.1 Pediatrics; 10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics, Special populations, Pediatrics. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Based on clinical studies, no apparent overall differences were observed in safety between older (patients ≥ 65 years) and younger patients (patients < 65 years) on fesoterodine extended-release tablets. Therefore, dosage adjustment for geriatric patients may not be required. See 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics; 8 ADVERSE REACTIONS, 8.2 Clinical Trial Adverse Drug Reactions; 10 CLINICAL PHARMACOLOGY 10.3 Pharmacok… https://pdf.hres.ca/dpd_pm/00075657.PDF PM date: MAY 23, 2024 Source product: TOVIAZ; DIN 02380021; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.